Objective-To investigate whether the presence of decay-accelerating factor (or CD55), an intrinsic complement regulator, protects against the development of vascular disease, given that complement activation can affect leukocytes and platelets. Methods and Results-Leukocyte-platelet complexes are critical for the initiation and progression of atherosclerosis and restenosis; however, the mechanism by which these processes promote vascular injury is incompletely defined. We performed femoral artery wire injury in Daf1 Ϫ/Ϫ mice and their wild-type controls. Leukocyte accumulation, cellular proliferation, and neointimal thickening were enhanced in Daf1 Ϫ/Ϫ mice versus wild-type mice. Deficiency of either the C3a or the C5a receptor, respectively, reversed the increased vascular inflammation, cellular proliferation, and neointimal formation in Daf1 Ϫ/Ϫ mice. Conclusion-Decay-accelerating factor control of C3a and C5a generation and prevention of the binding of these activation fragments to the C3a and C5a receptors are critical for the biological response to vascular injury. Targeting the C3a and C5a receptors may be useful for the prevention of neointimal hyperplasia. (Arterioscler Thromb Vasc Biol.
and progression of atherosclerosis 1 and restenosis. 2 In a series of experiments, we demonstrated that leukocyte engagement of platelet glycoprotein Ib␣ via the leukocyte ␤ 2 -integrin Mac-1 (␣ M ␤ 2 , CD11b/CD18) is critical for the biological response to endothelial-denuding vascular injury. 3, 4 However, an important gap exists regarding the fundamental molecular mechanisms that incite and amplify injury. Inflammation and thrombosis are 2 responses that are connected through a number of mechanisms, in particular the complement system, raising the possibility that complement activation fragments are important mediators.
During activation of the complement cascade, a key step is the cleavage of C3 or C4, resulting in the covalent binding of C3b or C4b to free hydroxyl and amino groups on targets; this process was reviewed by Fujita. 5 These fragments serve as sites for the assembly of C4b2a and C3bBb, the central amplification enzymes of the cascade. Interestingly, it has been shown that complement activation mobilizes leukocyte Mac-1 from intracellular storage pools and activates the integrin, 6 indicating that complement pathways are capable of modulating Mac-1-dependent vascular injury and repair responses. Complement components also interact specifically with platelets, which activate them and, in turn, promote thrombosis. 7, 8 . Conversely, activated platelets are capable of directly activating complement; specifically, platelet P-selectin can serve as a receptor for C3b and promote the generation of C3a/C5a and the deposition of C5b-9. 9 Because C3b or C4b activation fragments bind to free hydroxyl and amino groups present on self cell surfaces, their activities on self cells must be strictly controlled. Although this control is conferred in part by the serum complement regulators, factor H and C4 binding protein, it is provided principally by cell surface-associated "intrinsic" complement regulatory proteins. 10 Among these regulators, the first 11 described is decay-accelerating factor (DAF), a 70-kDa surface molecule that is widely expressed on essentially all cell types. DAF circumvents amplification of C3b deposition on self cells by rapidly dissociating any C4b2a and C3bBb 12-14 that assemble on self cell surfaces. Thus, DAF prevents focused C3b deposition, the formation of C5 convertases (C4b2a3b and C3bBb3b), and C5 cleavage that generates the C5a anaphylatoxin and initiates the membranolytic terminal pathway sequence. Thereby, DAF serves as a critical shield that protects against autologous complement attack. Another intrinsic regulatory protein, CD59, functions late at the pathway's lytic end point (ie, activation/insertion of C9). 15 If any C5b-8 assembly ensues despite failure to completely control C3/C5 convertases, or as a result of bystander activation independent of these enzymes, CD59 prevents uptake of C9 by cell-bound C5b-8 and thereby blocks C9 polymerization into C5b-9 n membrane attack complexes that bring about cell lysis. 16 Thus, this latter regulator serves as a backup that provides an additional layer of protection to self tissues.
Given that complement activation can affect leukocytes, platelets, and the vascular endothelium and that DAF controls complement activation on these cells, we investigated whether the presence of DAF modulates the biological response to vascular injury. We found that after femoral artery wire injury, leukocyte accumulation, cellular proliferation, and neointimal thickening are enhanced in Daf1 Ϫ/Ϫ mice compared with wild-type (WT) mice. Deficiency of either the C3a receptor (C3aR) or the C5a receptor (C5aR) reversed the increased susceptibility to vascular inflammation and neointimal formation. These results demonstrate that DAF control of C3a/C5a generation and consequent prevention of C3aR/C5aR signaling are critical for the biological response to vascular injury.
Methods

Mice
Male Daf1 Ϫ/Ϫ mice, aged 8 to 10 weeks, 17 that backcrossed greater than 10 generations on the C57BL/6 background were used. Although mice possess a second Daf gene (Daf2), 18 this gene encodes transmembrane-anchored DAF expressed principally in the testis. Daf1 Ϫ/Ϫ C5aR Ϫ/Ϫ and Daf1 Ϫ/Ϫ C3aR Ϫ/Ϫ doubly deficient mice on the C57BL/6 background were prepared, as described previously. 19 Mice were maintained in animal facilities at Case Western Reserve University School of Medicine, Cleveland, Ohio. Animal care and procedures were reviewed and approved by the Institutional Animal Care and Use Committees and performed in accordance with the guidelines of the American Association for Accreditation of Laboratory Animal Care and the National Institutes of Health.
Femoral Artery Injury
Male C57BL/6 mice, aged 8 to 10 weeks, were anesthetized on day 0 using ketamine, 80 mg/kg intraperitoneally, and xylazine, 5 mg/kg, intraperitoneally; wire injury of the femoral artery was performed, as described previously. 20, 21 All animals survived until the planned euthanasia without bleeding or infection.
Tissue Harvesting and Analysis
On 1, 5, or 14 days after vascular injury, anesthesia was administered; the chest cavity was opened; and the animals were euthanized by right atrial exsanguination. A 22-gauge butterfly catheter was inserted into the left ventricle for in situ pressure perfusion at 100 mm Hg with 0.9% saline for 1 minute, followed by fixation with 4% paraformaldehyde in 0.1-mol/L phosphate buffer, pH 7.3, for 10 minutes. The right and left femoral arteries were excised and immersed in buffered paraformaldehyde. Samples from the spleen and small intestine from 3 animals were harvested as control tissues for immunohistochemistry. All animals received 5-bromodeoxyuridine (BrdUrd), 50 mg/kg intraperitoneally, 18 hours and 1 hour before euthanasia.
The femoral arteries were embedded; and 2 cross sections, cut 1 mm apart, were stained with hematoxylin and eosin and the Verhoeff tissue elastin stain. A histologist (T.M.) blinded to the animal genotype measured the luminal, intimal, and medial areas of each cross-sectional plane using a microscope equipped with a charge-coupled device camera (Zeiss AxioCam MRc5, Carl Zeiss MicroImaging, Thornwood, NY) interfaced to a computer running National Institutes of Health Image. Immunopositive staining area was analyzed using computer-assisted imaging analysis (Zeiss Axiovision software Rel 4.5, Carl Zeiss MicroImaging). Results for the 2 planes of each artery were averaged. For immunohistochemistry, standard avidin-biotin procedures for mouse CD45 (leukocyte common antigen; BD Biosciences, San Diego, Calif), mouse neutrophils (monoclonal antibody 7/4; AbD Serotec, NC), mouse macrophages (Mac-3, monoclonal antibody M3/84; BD Biosciences), mouse platelets (antiglycoprotein IIb; BD Biosciences), and BrdUrd (DAKO, Carpinteria, Calif) were used. For each antibody, controls included species-specific nonimmune IgG and omission of the primary antibody. For CD45 and BrdUrd, immunostained sections were quantified as the number of immunostained positive cells per the total number of nuclei. For Mac-3, monoclonal antibody 7/4, C3dg, and glycoprotein IIb, staining was quantified as the percentage positive staining area as the fraction of immunopositive staining to total area measured.
Statistical Analysis
Data are presented as the meanϮSD unless otherwise indicated. Comparisons between WT and Daf1 Ϫ/Ϫ used a nonpaired t test. PϽ0.05 was considered significant. Statistical comparisons between Daf1 Ϫ/Ϫ , Daf1 Ϫ/Ϫ C3aR Ϫ/Ϫ , and Daf1 Ϫ/Ϫ C5aR Ϫ/Ϫ mice were performed using a 1-way ANOVA to determine a difference in mean values between the 3 groups, followed by t tests for the 3 pairwise comparisons when the ANOVA false-positive rate was less than 5%. For ANOVA with a false-positive rate of greater than 5%, the pairwise comparisons were reported to be statistically nonsignificant. For each end point, a Bonferroni corrective for 3 pairwise comparisons was applied, in which the t test PϽ0.02 was used to signify a false-positive rate of 5%.
Results
Femoral Artery Injury, Daf1 Expression, and Neointimal Formation
To determine whether DAF activity functions to modulate neointimal formation, we subjected WT and Daf1 Ϫ/Ϫ mice to transluminal wire injury of the femoral artery. Wire injury is accompanied by endothelial denudation, platelet and fibrin deposition, and prominent vascular inflammation. 20 -22 This model has been useful, to us and others, in demonstrating that inflammatory cell recruitment and function modulate neointimal formation. [21] [22] [23] Immunohistochemical staining of femoral arteries from WT mice showed robust expression of DAF within the smooth muscle-containing media in uninjured vessels (Figure 1) . As an important control, there was no DAF expression in Daf1 Ϫ/Ϫ arteries. Five days after wire injury in WT arteries, the expression of DAF was evident in the developing neointima, which is composed of predominantly inflammatory cells. There was progressive downregulation of DAF expression during the 14-day postinjury period. Consistent with this downregulation of DAF, wire injury was accompanied by the local accumulation of the complement fragment C3dg in the vessel wall during the postinjury period. C3dg staining was increased significantly in Daf1 Ϫ/Ϫ mice compared with WT mice 14 days after injury (percentage of C3dg-positive intimal area: Daf1 Ϫ/Ϫ mice versus WT mice, 51.1Ϯ8.3% versus 30.6Ϯ10.0%; Pϭ0.008).
Wire injury is associated with endothelial denudation and platelet deposition. We assessed platelet deposition 1 day after injury by staining for the platelet-specific glycoprotein ␣IIb. There was no significant difference (Pϭ0.19) in the ␣IIb-positive area between WT arteries (1710Ϯ630 m 2 ) and Daf1 Ϫ/Ϫ arteries (2410Ϯ890 m 2 ) (Supplemental Figure I ; available online at http://atvb.ahajournals.org).
In WT mice, neointimal thickening was evident 5 days after injury and progressed significantly between 5 days (1840Ϯ550 m 2 ) and 14 days (7020Ϯ8970 m 2 ) (Table) . In Daf1 Ϫ/Ϫ mice, neointimal thickening was increased by 155% at 14 days (Pϭ0.03) compared with WT mice (Table and Figure 2 ). There was no difference in the medial area at 14 days. The intima to media area ratio at 14 days was increased in Daf1 Ϫ/Ϫ compared with WT mice (0.90Ϯ0.30 versus 0.57Ϯ0.41; Pϭ0.01). Intimal thickening was accompanied by vessel enlargement (ie, "positive remodeling"), as determined by the external elastic lamina area measurements at 14 days. The external elastic lamina area was comparable in WT and Daf1 Ϫ/Ϫ mice.
Because evidence suggests that complement activation can be involved in cellular proliferation, 19 we assessed cellular proliferation by quantifying the incorporation of BrdUrd in WT and Daf1 Ϫ/Ϫ vessels after injury. Five days after injury, substantial proliferation was evident in WT arteries (17.3Ϯ9.2% of intimal cells and 7.1Ϯ3.3% of medial cells); this persisted for 14 days (11.4Ϯ9.1% of intimal cells and 4.1Ϯ3.7% of medial cells). Deficiency of Daf1 significantly enhanced intimal (205% increase; Pϭ0.002) and medial (286% increase; PϽ0.001) proliferation at 5 days and intimal (174% increase; Pϭ0.02) and medial (249% increase; PϽ0.001) proliferation at 14 days. These data provide direct evidence that DAF ameliorates the proliferative response to vascular injury.
Deficiency of Daf1 and Leukocyte Recruitment
Transluminal wire injury of the femoral artery is accompanied by prominent vascular inflammation. 20 Our studies implicated DAF in this process because altered leukocyte accumulation within vessels was observed in injured arteries from Daf1 Ϫ/Ϫ compared with WT mice. At 5 days after injury, inflammatory cells (percentage CD45 positive) accu- We expanded the CD45 analysis by immunostaining with cell-specific markers. The accumulation of neutrophils (monoclonal antibody 7/4 -positive cells) in the developing neointima (WT versus Daf1 Ϫ/Ϫ mice, 15.8Ϯ11.8% versus 33.9Ϯ16.2%; Pϭ0.02) and media (WT versus Daf1 Ϫ/Ϫ mice, 9.1Ϯ6.3% versus 16.4Ϯ9.4%; Pϭ0.09) at 5 days was increased by 214% and 180%, respectively, in Daf1 Ϫ/Ϫ mice compared with WT mice. The accumulation of macrophages (Mac-3-positive cells) in the developing neointima (WT versus Daf1 Ϫ/Ϫ mice, 24.9Ϯ12.1% versus 43.9Ϯ17.9%; Pϭ0.03) and media (WT versus Daf1 Ϫ/Ϫ mice, 18.1Ϯ13.5% versus 31.4Ϯ10.7%; Pϭ0.048) at 5 days was increased by 176% and 173%, respectively, in Daf1 Ϫ/Ϫ mice. Taken together, these data indicate that DAF modulates the recruitment and accumulation of neutrophils and macrophages after vascular injury.
Combined Deficiency of Daf1 and C3aR or C5aR Reverses the Increased Vascular Inflammation and Neointimal Formation in Daf1 ؊/؊ Mice
To gain insight into the mechanism by which deficiency of DAF and consequent increased self cell surface complement activation alters vascular inflammation and proliferation in response to vascular injury, we performed studies with Daf1 Ϫ/Ϫ C5aR Ϫ/Ϫ and Daf1 Ϫ/Ϫ C3aR Ϫ/Ϫ double-knockout mice. In both Daf1 Ϫ/Ϫ C3aR Ϫ/Ϫ and Daf1 Ϫ/Ϫ C5aR Ϫ/Ϫ mice, we observed near reversal of the increased vascular inflammation, cellular proliferation, and neointimal thickening observed in Daf1 Ϫ/Ϫ mice (Figure 3 ).
Because we observed progressive downregulation of DAF expression during the 14-day postinjury period in WT mice that was accompanied by the accumulation of the complement activation fragments, we investigated the effect of targeting C3aR and C5aR by performing injury experiments in singly deficient C3aR Ϫ/Ϫ and C5aR Ϫ/Ϫ mice. Inflammatory cell recruitment and cellular proliferation were attenuated in C3aR Ϫ/Ϫ and C5aR Ϫ/Ϫ compared with WT mice (Supplemental Figure II) . Taken together, these results indicate that DAF control of C3a/C5a generation and prevention of the binding of these activation fragments to C3aR/C5aR are critical for vascular injury and repair responses.
Discussion
This study demonstrates that DAF modulates vascular injury. In its absence, leukocyte accumulation, cellular proliferation, and neointimal thickening were enhanced after endothelialdenuding wire injury. Combined deficiency of either C3aR or C5aR reversed the increased susceptibility to vascular inflammation and neointimal formation. These observations establish that DAF control of C3a/C5a generation and consequent C3aR and C5aR signal transduction are critical for the biological response to vascular injury.
This study adds to the emerging evidence that intrinsic complement regulators, such as DAF and CD59, play an important role in modulating cardiovascular disease, including atherosclerosis 24 -27 and ischemia-reperfusion injury. 28 Interestingly, there is conflicting evidence regarding the protective effect of DAF in atherosclerosis, with one group 26 reporting enhanced lesion formation in Dafl1 Ϫ/Ϫ mice crossed to low-density lipoprotein receptor-deficient mice and another 27 showing no effect when crossed to apolipoprotein E-deficient mice. In our hands, deficiency of Daf1 is associated with enhanced atherosclerotic lesion formation on both backgrounds (M.S. and M.E.M., unpublished data, 2008). Although our results strongly suggest that targeting C3aR/C5aR interactions may be useful in preventing neointimal formation, they do not identify the cells in which these interactions are occurring or assign the source of the complement (namely, local [leukocyte, platelet, or smooth muscle cell derived] versus systemic). Although it is widely believed by many that the liver is the sole source of complement, work as early as the 1980s has shown that, at sites of inflammation, monocytes and macrophages locally produce C3 and that this locally synthesized C3 participates in opsonizing pathogens extravascularly. 29 More importantly, recent work by several groups 30 -33 has shown that vascular endothelial cells and leukocytes 19 and smooth muscle cells 34 synthesize complement in response to a variety of stimuli. In the case of immune responses, when antigen-presenting cells interact with T cells, both partners rapidly (within 5 minutes) turn on the synthesis of C3, fB, fD, C5, C3aR, and C5aR and interactions of locally generated C3a/C5a with upregulated C3aR/C5aR provide both costimulatory and survival signals to T cells. 35 These studies of immune cells have shown that amplification of C3aR/C5aR signal transduction drives proliferation of T cells and that termination of this signal transduction halts T-cell proliferation and evokes programmed cell death. More importantly, these findings have revealed that amplified C3a/C5a•C3aR/C5aR interactions versus halted C3a/C5a•C3aR/C5aR interactions that confer proliferation versus programmed cell death, respectively, are controlled by surface DAF. 36 Recent observations in dendritic, 19 liver, 37 and cancer 31, 38 cells indicate that this is a general process that, according to all available data, likely applies to all cell types.
Arterial smooth muscle cells have the ability to synthesize complement components and regulators, which are modulated by cytokines. 34 Platelets not only express, but are also capable of synthesizing complement and complement regulatory proteins from preformed mRNAs. After their generation from complex cytoplasmic extensions of bone marrow megakaryocytes, platelets retain megakaryocyte-derived mRNAs 39 and the translational machinery for protein biosynthesis. 40 Human platelets also possess a functional spliceosome, a complex that processes precursor mRNAs into a mature message that is translated into a protein. 41 Highly purified human platelets contain greater than 2000 transcripts, 42, 43 including transcripts for C1qR, C3, C3aR, C3b/ 4bR, C4a, C5, C5aR, C7, C8a, C8b, C9, and DAF.
Wire injury produces endothelial denudation, platelet deposition, thrombin generation, and an elaboration of cytokines, chemokines, and growth factors (eg, platelet-derived growth factor). Interestingly, upregulation of DAF expression by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway has been reported to protect vascular cells from complement-mediated injury. 44 Although these results strongly suggest that targeting C3aR/C5aR interactions may be useful in preventing neointimal formation, they do not identify the cells in which these interactions are occurring or assign the source of the complement (ie, local versus systemic). A strategy using bone marrow and liver transplantation with WT, Daf1 Ϫ/Ϫ , and doubly deficient C3aR Ϫ/Ϫ C5aR Ϫ/Ϫ or C3a Ϫ/Ϫ C5a Ϫ/Ϫ mice will be required to delineate the relative contributions of liver, hematopoietic (leukocyte), and nonhematopoietic (smooth muscle and endothelial) cells.
In conclusion, this study demonstrates that DAF control of complement activation and consequent C3aR and C5aR signal transduction are critical for the biological response to vascular injury, and strongly suggests that targeting complement may be useful in preventing neointimal formation in restenosis, atherosclerosis, and transplant vasculopathy.
